Long-term outcomes of surgery for advanced ovarian cancer during interval cytoreduction
Aim. To compare long-term oncological outcomes of extended, combined, and standard surgical interventions.Sekerskaya M.N., Nikogosyan S.O., Shevchuk A.S., Kuznetsov V.V., Kantieva D.M., Tarachkova E.V.
Materials and methods. The study included women with histologically verified T3-4N0-1M0-1ovarian cancer. Patients in group A underwent extended and combined surgical interventions, while patients in group B were subjected to standard surgery. In the preoperative period, all patients received 6 courses of PCT, a combination of platinum and taxanes. We compared the rates of achieving optimal and conditionally radical operations after extended and combined operations and standard surgical procedures at the stage of interval cytoreduction. The structure, rates and causes of intra- and postoperative complications were estimated. The endpoints analyzed were overall and recurrence-free survival.
Results. From 2010 to 2018, we selected archived medical records of 150 patients with advanced ovarian cancer (stages IIIC-IV). Long-term follow-up data were available for 143 (95.3%) patients. In groups A and B, complete cytoreduction was achieved in 56.7% and 40.8% of patients, respectively. In group A, 10 (33.3%) patients had intraoperative complications; 6 (19.9%) and 2 (6.7%) patients had grade I-II and grade III-IV postoperative complications, respectively (p = 0.82). In group B, intraoperative complications were seen in 16 (13.3%) patients. Postoperative grade I-II and grade III-IV complications were observed in 22 (18.3%) and 7 (5.8%) patients, respectively. The median follow-up in the study and control group was 39 and 29 months, respectively. The median of RFS in the study group was not achieved; in the control group, it was 10.48 months (CI 95% 8.233-12.66). In the study group, three-year recurrence-free survival was 59%. In the control group, three-year recurrence-free survival was 21%. Median OS in the study group was not achieved; in the control group, it was 37.3 months. (CI 95% 30.51–44.07). In the study group, three-year overall survival was 79 months. In the control group, three-year overall survival was 43%.
Conclusion. Combined and extended surgical interventions for advanced ovarian cancer at the stage of interval cytoreduction are feasible and associated with better oncological outcomes of complete cytoreduction.
Keywords
ovarian cancer
surgical treatment
interval cytoreduction
overall and recurrence-free survival
References
- Horowitz N.S., Larry M.G., Miller A., C.A. Hamilton, B. Rungruang, N. Rodriguez, et al., Predictive modeling for determination of microscopic residual disease at primary cytoreduction: an NRG Oncology/Gynecologic Oncology Group 182 Study, Gynecol. Oncol. 2018; 148(1): 49–55. DOI: 10.1016/j.ygyno.2017.10.011
- Whitney C.W., Spirtos N. Gynecologic Oncology Group Surgical Procedures Manual. 2010 January: [Электронный документ] (https:// gogmember.org/manuals/pdf/surgman.pdf).
- Peiretti M., Zanagnolo V., Aletti G.D., Bocciolone L., Colombo N., Landoni F. et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubalcancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol. 2010; 119(2): 259–64. http://dx.doi.org/10.1016/j.ygyno.2010.07.032
- Mueller J.J., Zhou Q.C., Iasonos A., R.E. O’Cearbhaill, F.A. Alvi, H.A. El, et al., Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol. 2016;140: 436–42.
- Wallace S., Kumar A., Mc Gree M., Weaver A. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. Gynecol Oncol. 2017; 145(1): 21–26. doi: 10.1016/j.ygyno. 2017.01.029. Epub 2017 Jan 31.
- Vergote I., Trope C.G., Amant F., et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363: 943–53. doi: 10.1056/NEJMoa0908806
- Kehoe S., Hook J., Nankivell M., et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; 386: 249–57. doi: 10.1016/S0140-6736(14)62223-6.
- Chi D.S., Eisenhauer E.L., Zivanovic O., et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009; 114: 26–31. doi: 10.1016/j.ygyno.2009.03.018
Received 23.12.2019
Accepted 26.12.2019
About the Authors
Maria N. Sekerskaya, graduate student of the department of combined and radiation methods for the study of gynecological oncological diseases of the Research Institute of KO them. Trapeznikov «N.N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO). E-mail: gynonco16@gmail.com115478 Russia, Moscow, Kashirskoye highway 23
Seda O. Nikoghosyan, MD, oncologist-gynecologist of the Research Institute of KO them. Trapeznikov of the National Medical Research Center of Oncology «N.N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO). Moscow, Russia. E-mail: gynonco16@gmail.com
115478 Russia, Moscow, Kashirskoye highway 23
Aleksey S. Shevchuk, candidate of medical sciences, head of the oncological department of surgical treatment methods No. 8 (oncogynecology) of the Research Institute of KO them. Trapeznikov «N.N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO). E-mail: gynonco16@gmail.com
115478 Russia, Moscow, Kashirskoye highway 23
Viktor V. Kuznetsov, MD, professor, leading researcher at the Oncological Department of Surgical Treatment Methods No. 8 (Oncogynecology), of the Research Institute of KO them. Trapeznikov «N.N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO). Moscow, Russia. Email gynonco16@gmail.com
115478 Russia, Moscow, Kashirskoye highway 23
Dayana M. Kantieva, Clinical Resident of the Oncology Department of Medicinal Methods of Treatment No. 3 of the N.N.Trapeznikov Research Institute of Clinical Oncology NN Blokhin ”Ministry of Health of the Russian Federation.
115478 Russia, Moscow, Kashirskoye highway 23
Elena V. Tarachkova,, Candidate of Medical Sciences, Assistant of the Department of Radiology and Radiology of the Department of Surgeryussian Medical Academy of Postgraduate Education" of the Ministry of Health of Russia. E-mail: a doctorkid@yandex.ru
123995 Russia, Moscow, ul. Barrikadnaya, 2/1, p. 1
For citation: Sekerskaya M.N., Nikogosyan S.O., Shevchuk A.S., Kuznetsov V.V., Kantieva D.M., Tarachkova E.V. Long-term outcomes of surgery for advanced ovarian cancer during interval cytoreduction.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2020; 1(Suppl):44-9. (in Russian)
https://dx.doi.org/10.18565/aig.2020.1suppl.44-49
Similar Articles
